NO20042584L - Dibenzylaminforbindelser og farmasoytisk anvendelse derav - Google Patents

Dibenzylaminforbindelser og farmasoytisk anvendelse derav

Info

Publication number
NO20042584L
NO20042584L NO20042584A NO20042584A NO20042584L NO 20042584 L NO20042584 L NO 20042584L NO 20042584 A NO20042584 A NO 20042584A NO 20042584 A NO20042584 A NO 20042584A NO 20042584 L NO20042584 L NO 20042584L
Authority
NO
Norway
Prior art keywords
alkyl group
hydrogen atom
pharmaceutical use
halogen atom
halogen
Prior art date
Application number
NO20042584A
Other languages
English (en)
Other versions
NO328886B1 (no
Inventor
Hisashi Shinkai
Kimiya Maeda
Hironobu Nagamori
Hiroshi Nakamura
Yasunori Suzuki
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20042584L publication Critical patent/NO20042584L/no
Publication of NO328886B1 publication Critical patent/NO328886B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
NO20042584A 2002-08-30 2004-06-18 Dibenzylaminforbindelser, anvendelse av forbindelsene, farmasoytiske midler omfattende forbindelsene samt CETP-aktivitetsinhibitor NO328886B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002255604 2002-08-30
JP2003107161 2003-04-10
PCT/JP2003/011041 WO2004020393A1 (ja) 2002-08-30 2003-08-29 ジベンジルアミン化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
NO20042584L true NO20042584L (no) 2004-06-18
NO328886B1 NO328886B1 (no) 2010-06-07

Family

ID=31980551

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042584A NO328886B1 (no) 2002-08-30 2004-06-18 Dibenzylaminforbindelser, anvendelse av forbindelsene, farmasoytiske midler omfattende forbindelsene samt CETP-aktivitetsinhibitor

Country Status (25)

Country Link
US (2) US7332514B2 (no)
EP (2) EP1533292B1 (no)
KR (1) KR100634195B1 (no)
CN (1) CN1289467C (no)
AT (1) ATE353870T1 (no)
AU (1) AU2003261826B2 (no)
BR (1) BR0306208A (no)
CA (1) CA2464846C (no)
CY (1) CY1106425T1 (no)
CZ (1) CZ2004627A3 (no)
DE (1) DE60311821T2 (no)
DK (1) DK1533292T3 (no)
ES (1) ES2277142T3 (no)
HK (1) HK1077567A1 (no)
IL (2) IL161559A0 (no)
MX (1) MXPA04005350A (no)
NO (1) NO328886B1 (no)
NZ (1) NZ532494A (no)
PT (1) PT1533292E (no)
RU (1) RU2293078C2 (no)
SI (1) SI1533292T1 (no)
SK (1) SK2332004A3 (no)
TR (1) TR200401413T1 (no)
WO (1) WO2004020393A1 (no)
ZA (1) ZA200403137B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
KR100634195B1 (ko) * 2002-08-30 2006-10-16 니뽄 다바코 산교 가부시키가이샤 디벤질아민 화합물 및 그 의약 용도
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
KR20070087197A (ko) * 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
AU2008201550B2 (en) * 2003-09-26 2011-02-10 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
CN1863778A (zh) * 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP4587685B2 (ja) * 2004-03-23 2010-11-24 セントラル硝子株式会社 ３−ホルミル−５−トリフルオロメチルベンゾニトリル誘導体とその製造方法
KR20070007112A (ko) * 2004-03-26 2007-01-12 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
EP1737811B1 (en) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
KR100854864B1 (ko) 2004-08-05 2008-08-28 에프. 호프만-라 로슈 아게 인돌, 인다졸 또는 인돌린 유도체
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1942904A4 (en) * 2005-09-30 2009-11-18 Merck & Co Inc CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
US7935727B2 (en) * 2005-10-19 2011-05-03 Merck Sharp & Dohme Corp. CETP inhibitors
BRPI0620020A2 (pt) * 2005-12-22 2011-10-25 Takeda Pharmaceutical preparação sólida, e, partìcula revestida
AU2006330072B2 (en) * 2005-12-28 2012-08-02 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
EP1968941A1 (en) * 2005-12-29 2008-09-17 Novartis AG Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30117A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
US7572823B2 (en) * 2006-02-07 2009-08-11 Hoffmann-La Roche Inc. Heteroaryl carboxamide compounds
CA2641451C (en) * 2006-02-09 2012-10-02 Merck & Co., Inc. Polymer formulations of cetp inhibitors
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
GB0609268D0 (en) * 2006-05-10 2006-06-21 Novartis Ag Organic compounds
AR060873A1 (es) 2006-05-10 2008-07-16 Novartis Ag Derivados biciclicos como inhibidores de cetp
KR20090018946A (ko) * 2006-05-11 2009-02-24 노파르티스 아게 Ｃｅｔｐ 억제제로서의 벤질아민 유도체
WO2008059513A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Compounds suitable as modulators of hdl
KR100821688B1 (ko) 2006-08-10 2008-04-11 (주)유케이케미팜 암로디핀 라셈화물의 입체이성질체의 분리방법과 그의친수성 약물 및 그의 제조방법
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
CA2683534C (en) * 2007-04-13 2015-02-24 Kowa Company, Ltd. Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
JP5319457B2 (ja) * 2008-08-25 2013-10-16 興和株式会社 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
CN102300839B (zh) * 2008-11-28 2014-12-10 兴和株式会社 反式-{4-[(烷基氨基)甲基]环己基}乙酸酯的制备方法
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
JP2014520795A (ja) 2011-07-08 2014-08-25 ノバルティス アーゲー 高トリグリセリド対象においてアテローム性動脈硬化症を治療する方法
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
CA2850022C (en) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
CN105246877A (zh) 2013-05-31 2016-01-13 兴和株式会社 具有二苄胺结构的嘧啶化合物的新形态
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US20190167767A1 (en) 2016-07-27 2019-06-06 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576830A (en) 1966-08-12 1971-04-27 Sumitomo Chemical Co Amides containing sulfur
US4064125A (en) 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
US4473579A (en) 1982-01-26 1984-09-25 American Cyanamid Company Antiatherosclerotic tetrasubstituted ureas and thioureas
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US5446207A (en) 1993-09-01 1995-08-29 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
JPH09512556A (ja) 1994-04-29 1997-12-16 サノフィ ウィンスロップ，インコーポレイティド ＩＬ−１βプロテアーゼ・インヒビターとしてのハロメチル・アミド
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
US5834514A (en) 1995-05-30 1998-11-10 Vertex Pharmaceuticals, Incorporated Halomethyl amides as IL-1β protease inhibitors
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
NZ503712A (en) 1997-10-02 2003-07-25 Sankyo Co Amidopropionic acid derivatives
AU753540B2 (en) * 1998-03-05 2002-10-24 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents
SE9802209D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
JP2002525350A (ja) * 1998-09-25 2002-08-13 モンサント カンパニー コレステロールエステル輸送タンパク質活性阻害に有効な置換されたｎ−脂肪族−ｎ−芳香族第三級ヘテロアルキルアミン
DE69925612T2 (de) * 1998-09-25 2006-03-16 Monsanto Co., Chicago (r)-chirale halogenierte 1-substituierte amino-(n+1)-alkanolen für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
EP1183229B1 (en) 1999-05-17 2005-10-26 Novo Nordisk A/S Glucagon antagonists/inverse agonists
UA73307C2 (uk) 1999-08-05 2005-07-15 Куміаі Кемікал Індастрі Ко., Лтд. Похідна карбамату і фунгіцид сільськогосподарського/садівницького призначення
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
WO2004005266A1 (en) * 2002-07-03 2004-01-15 F. Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
KR100634195B1 (ko) * 2002-08-30 2006-10-16 니뽄 다바코 산교 가부시키가이샤 디벤질아민 화합물 및 그 의약 용도

Also Published As

Publication number Publication date
EP1829858A3 (en) 2007-10-03
CZ2004627A3 (cs) 2004-10-13
NZ532494A (en) 2006-03-31
US20080146620A1 (en) 2008-06-19
RU2004119546A (ru) 2005-08-10
EP1829858A2 (en) 2007-09-05
ATE353870T1 (de) 2007-03-15
SI1533292T1 (sl) 2007-08-31
CA2464846C (en) 2010-04-06
WO2004020393A1 (ja) 2004-03-11
US7807701B2 (en) 2010-10-05
US20050059810A1 (en) 2005-03-17
EP1533292A1 (en) 2005-05-25
HK1077567A1 (en) 2006-04-13
AU2003261826B2 (en) 2006-02-02
EP1533292A4 (en) 2005-11-02
CY1106425T1 (el) 2011-10-12
DE60311821D1 (de) 2007-03-29
KR100634195B1 (ko) 2006-10-16
IL161559A (en) 2009-12-24
EP1533292B1 (en) 2007-02-14
TR200401413T1 (tr) 2005-06-21
NO328886B1 (no) 2010-06-07
PT1533292E (pt) 2007-05-31
CN1289467C (zh) 2006-12-13
US7332514B2 (en) 2008-02-19
BR0306208A (pt) 2004-10-13
RU2293078C2 (ru) 2007-02-10
KR20040075908A (ko) 2004-08-30
CN1617850A (zh) 2005-05-18
SK2332004A3 (en) 2004-12-01
DE60311821T2 (de) 2007-10-31
ES2277142T3 (es) 2007-07-01
AU2003261826A1 (en) 2004-03-19
CA2464846A1 (en) 2004-03-11
DK1533292T3 (da) 2007-06-04
IL161559A0 (en) 2004-09-27
MXPA04005350A (es) 2004-09-27
ZA200403137B (en) 2005-06-29

Similar Documents

Publication Publication Date Title
NO20042584L (no) Dibenzylaminforbindelser og farmasoytisk anvendelse derav
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
HK1147490A1 (en) Condensed aminodihydrothiazine derivative
NO20060219L (no) Forbindelser
EA200601235A1 (ru) Производные тиазола
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
TW200619212A (en) Morpholine derivatives
AR006619A1 (es) Derivados de aminopiridina, composicion farmaceutica que los contien, metodo para elaborar un medicamento, intermediario quimico para la produccionde dichos compuestos y procedimiento para preparar los derivados de aminopiridina
DK393486D0 (da) Dihydropyridin-derivater og fremgangsmaade til fremstilling deraf
EP1908752A4 (en) NEW 2-CHINOLO DERIVATIVES
DE60045821D1 (de) Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
HUP0201863A2 (hu) Új morfolinszármazékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
NO20053302L (no) Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
NO955071D0 (no) abeo-Ergolin-derivater som 5HT1A-ligander
TW200508211A (en) 2-naphthylimino-1,3-thiazine derivatives
HUP0201255A2 (hu) Új pirimidin-4-on-származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyászati készítmények
HUP0202296A2 (hu) Eljárás szubsztituált benzizotiazolszármazékok előállítására

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees